Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicholas A. Maskell has a total of 514 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Randomised pilot and feasibility study comparing video-assisted thoracoscopic partial pleurectomy-decortication with indwelling pleural catheter for trapped lung in pleural mesothelioma

    by Robert Campbell Rintoul, Carol Freeman, Nicholas A Maskell, John Edwards, Aman Coonar, Victoria Hughes, Najib M Rahman, Linda Sharples

    MesoTRAP aimed to provide preliminary data comparing the efficacy of indwelling pleural catheter (IPC) versus video-assisted thoracoscopic pleurectomy-decortication for trapped lung in pleural mesothelioma. Trapped lung prevalence was 11% (110/988). Over 31 months, 17 centres randomised 10 patients versus 38 planned. Thirteen non-randomised patients entered an observational substudy. Nine randomised patients reported daily visual analogue scale scores for pain and dyspnoea, but measurements varied substantially within and between patients, precluding meaningful analysis. Slow recruitment due to poor performance status precluding surgery prohibits a full trial. In the absence of high-level evidence, we conclude that the least invasive approach to trapped lung, namely IPC, should be considered in line with current guidance. Trial registration number NCT03412357.

  • Review of the British Thoracic Society Winter Meeting 26–29 November 2025

    by Cara A Flynn, Aleksandra (Ola) Howell, Imran Howell, Anthony W Martinelli, Christine Mwasuku, Mona Bafadhel, Nicholas A Maskell, Richard Ek Russell

    Background: The 2025 British Thoracic Society (BTS) Winter Meeting delivered 3 days of cutting-edge science, clinical innovation and networking in wintry Westminster. Over 2500 attendees from 36 countries gathered to share advances shaping the future of respiratory medicine. Content: The programme opened with a session focused on emerging clinical trial data, showcasing pragmatic and mechanistic studies designed to address real-world challenges in respiratory care, setting the tone for a meeting focused on impact and innovation. Translational research featured strongly throughout the meeting, with organoids, precision-cut lung slices and air-liquid interface cultures providing new perspectives on disease mechanisms and therapeutic targets. Early career investigators presented discoveries in eosinophilic chronic obstructive pulmonary disease biology, microbiome-driven viral susceptibility and resistance risks in novel bronchiectasis therapies, while midcareer leaders advanced understanding of familial interstitial lung disease and virus–host interactions. Plenary sessions tackled pressing challenges, from air pollution and breathlessness diagnostics to genetic drivers of pulmonary hypertension, complemented by guest lectures on immune regulation, vaccine-preventable illness and drug discovery. Additionally, the meeting highlighted workforce transformation, emphasising the role of nurses, allied health professionals and pharmacists in delivering integrated, digitally enabled care. Conclusion: Reminding us that progress rests on both scientific endeavour and enduring professional bonds, the 2025 BTS Winter Meeting reaffirmed that respiratory research is for everyone—an essential driver of advancement across disciplines. Multidisciplinary working and inclusive engagement will be key to shaping future care and ensuring that innovation translates into better outcomes for patients worldwide.


  • Open Access

    Time to next procedure in patients with malignant pleural effusion undergoing aspiration: derivation and initial validation of the RED score

    by Eleanor K Mishra, Helen Davies, Syed Hamza Abbas, Cheryl Hardy, Dominic T Beith, Dheeraj Sethi, Toshit Sapkal, Alguili Elsheikh, Asfandyar Yousuf, Emma L Hedley, et al.

    Introduction: In patients with malignant pleural effusions (MPE), pleural fluid reaccumulates at variable rates following therapeutic aspiration. The aim of this study was to identify variables which predict time to next procedure and use them to develop a predictive score. Methods: This prospective observational cohort study in 10 British hospitals recruited patients with known or suspected malignant effusions undergoing therapeutic aspiration. Follow-up lasted 3 months and assessed time to next clinically indicated pleural procedure. Regression analysis was performed to identify independent variables predicting time to next procedure, and a score derived. Initial validation was done in two external cohorts. Measurements and main results: 241 patients were recruited. Within the derivation cohort (n=180), baseline respiratory rate (R), pleural effusion depth on ultrasound (E) and dyspnoea measured using a visual analogue scale (D) (combined to form the RED score) were independent predictors of time to next procedure. Predictive models provided areas under the receiver operator curve of 0.73 and 0.75. Initial validity testing in two cohorts (n=31, n=57) demonstrated reasonable predictive value. Conclusions: In patients with MPE, baseline respiratory rate, pleural effusion depth on ultrasound and dyspnoea predict time to next procedure. Trial registration number: ISRCTN16567838 .


  • Management of Malignant Pleural Effusions

    by Mattew Shorthose, Geraldine A. Lynch, Nick A. Maskell

  • Management of Malignant Pleural Effusions

    by Mattew Shorthose, Geraldine A. Lynch, Nick A. Maskell

  • Future of academic respiratory medicine: near crisis point

    by Steven Walker, Nick Maskell

    Rates of chronic lung diseases are increasing, with respiratory diseases now responsible for 5 of the top 10 causes of death.2 Despite these challenges, the medical research workforce has diminished. 24% fewer medically trained research staff have been appointed over the last decade. As an overall proportion of the consultant workforce, the number of clinical academic consultants has almost halved to 3%.1 The problem is particularly pronounced in respiratory medicine. Compared with other Western European countries, the UK is an outlier, spending the least on respiratory research. Respiratory medicine accounted for only 4% of the NIHR fellowships (PhD and mid-career) and 3% of NIHR grant awarded in 2023. No respiratory doctors were recipients of the 58 NIHR Senior Investigator awards in 2024.3


  • Open Access

    Pragmatic non-inferiority Randomised trial Investigating Needle aspiration versus ChEst drain for Secondary Spontaneous Pneumothorax (the PRINCE-SSP study): study protocol for a randomised non-inferiority trial

    by Steven Walker, Ellie Taylor, Amy McAndrew, Edward Carlton, Ella Chaudhuri, Pooja Ghorpade, Charlotte Goodwin, James Connors, Heather Cook, Ramon Luengo-Fernandez, et al.

    Introduction Secondary spontaneous pneumothorax (SSP) is a medical emergency where the lung collapses in the presence of underlying chronic lung disease. Current international clinical guidelines advise intercostal drain (ICD) insertion for SSP. However, in a previous small study needle aspiration (NA) has been shown to reduce length of hospital stay (LOHS) and reduce complications. We are evaluating the clinical and cost-effectiveness of an initial NA approach to the management of patients with SSP in the United Kingdom. Methods and analysis The PRINCE-SSP (Pragmatic non-inferiority Randomised trial Investigating Needle aspiration vs ChEst drain for Secondary Spontaneous Pneumothorax) trial is a pragmatic, multicentre, open-label, parallel, two-group, randomised, non-inferiority trial to establish whether NA for SSP is non-inferior in terms of LOHS compared with ICD. We aim to recruit 110 patients from at least 15 UK NHS hospitals, over 18 months. Participants allocated to the intervention (NA) group will have an NA inserted at the presentation. Those allocated to the comparator (usual care) group will have an ICD inserted. Participants are followed up for 30 days. The primary outcome measure is initial LOHS, up to day 30 postrandomisation. Secondary outcomes include (but are not limited to) total LOHS including readmissions, complications, cost-effectiveness and patient-reported quality of life. Ethics and dissemination This trial received Health Research Authority (HRA) approval from Wales Research Ethics Committee seven ethics committee (23/WA/0085). Results will be submitted for publication in a peer-reviewed journal. A plain English summary of the trial results will be prepared and disseminated with the help of our patient advisory group, including via social media, and provided to trial participants via post or email according to their preference. Trial registration number ISRCTN12644940.


  • Top Cited Papers

    Joint ERS/EACTS/ESTS clinical practice guidelines on adults with spontaneous pneumothorax

    by Steven Walker, Robert Hallifax, Sara Ricciardi, Deirdre Fitzgerald, Marlies Keijzers, Olivia Lauk, Jesper Petersen, Luca Bertolaccini, Uffe Bodtger, Amelia Clive, et al.

    Background: The optimal management for spontaneous pneumothorax (SP) remains contentious, with various proposed approaches. This joint clinical practice guideline from the ERS, EACTS and ESTS societies provides evidence-based recommendations for the management of SP. Methods: This multidisciplinary Task Force addressed 12 key clinical questions on the management of pneumothorax, using ERS methodology for guideline development. Systematic searches were performed in MEDLINE and Embase. Evidence was synthesised by conducting meta-analyses, if possible, or narratively. Certainty of evidence was rated with GRADE (Grading of Recommendations, Assessment, Development and Evaluations). The Evidence to Decision framework was used to decide on the direction and strength of the recommendations. Results: The panel makes a conditional recommendation for conservative care of minimally symptomatic patients with primary spontaneous pneumothorax (PSP) who are clinically stable. We make a strong recommendation for needle aspiration over chest tube drain for initial PSP treatment. We make a conditional recommendation for ambulatory management for initial PSP treatment. We make a conditional recommendation for early surgical intervention for the initial treatment of PSP in patients who prioritise recurrence prevention. The panel makes a conditional recommendation for autologous blood patch in secondary SP patients with persistent air leak (PAL). The panel could not make recommendations for other interventions, including bronchial valves, suction, pleurodesis in addition to surgical resection or type of surgical pleurodesis. Conclusions: With this international guideline, the ERS, EACTS and ESTS societies provide clinical practice recommendations for SP management. We highlight evidence gaps for the management of PAL and recurrence prevention, with research recommendations made.


  • Open Access

    Recent Advances in Mesothelioma

    by Geraldine A. Lynch, Nick A. Maskell, Anna Bibby

    Purpose of Review: Pleural mesothelioma (PM) is a rare but fatal cancer of the pleural surface. Most patients have a poor prognosis, despite treatment advances which have improved outcomes. Recent research has focused on improving diagnosis, prognostication and monitoring through radiological, histological and molecular techniques. This review will cover its clinical implications and highlight areas where practice is changing. Recent Findings: Changes in tumour classification and histological reporting have formalised the differentiation between benign, pre-malignant and malignant pleural disease. CT and thoracic ultrasound (TUS) have good diagnostic yields for pleural biopsy, but PET-CT does not increase diagnostic yield for repeat sampling. immunohistochemistry (IHC) staining for BAP1 and MTAP/CDKN2A pathological samples can increase diagnosis rates, while serum mesothelin shows promise for disease monitoring. Phase 3 RCT results mean dual immunotherapy is the new standard of care, whereas there is no role for extended pleurectomy decortication surgery for PM. Summary: Best practice for PM diagnosis and management is changing at pace. Key areas for future research involve improving PM diagnostics, therapeutics and targeted therapies. An awareness of active research and clinical trials is essential for clinicians to seek for the best outcomes for their patients.